A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction

Wang, Ying; Liu, Xiaocheng; Zhang, Guang-Wei; Zhao, Jian; Zhang, Jiemin; Shi, Rui; Yun-zhou, Huang; Chun-hua, Zhao; Tian-jun, Liu; Song, Cunxian; Lu, Feng Hwa; Yang, Qin; He, Guo‐Wei

doi:10.1093/cvr/cvp229

Cited by 19 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, most studies have focused on the short-term effects of BMSC transplantation (14)(15)(16)(17)(18)(19)(20), and studies on medium and long-term effects are few (21). Intramyocardial injection of MSCs has been demonstrated to be safe in large animal models (5,11), and in the present study, 6 months following intramyocardial injection of Flk1 + CD34 + CD3 -BMSCs, SPECT detection indicated that the myocardial filling defect was reduced and LV ejection fraction was significantly improved in AMI models injected with BMSCs compared with uninjected models. Histopathological examination indicated that the area covered by the myocardial infarction and the percentage of cells undergoing apoptosis were reduced; and the percentage of survived myocardial tissue and the vessel densities were augmented, following BMSC injection (P<0.05, compared with controls).…”

Section: Discussionmentioning

confidence: 99%

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Zhao

Liu

Kong

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract.The aim of the current study was to confirm the effect and elucidate the mechanism of bone marrow mesenchymal stem cells (BMSCs) in acute myocardial infarction (AMI). AMI was induced in mini-swine by ligating the left anterior descending coronary artery, and BMSCs (1x10 7 ) were injected via a sterile microinjection into the ischemic area. Six months postoperatively, electrocardiograph-gated single photon emission computed tomography revealed that the myocardial filling defect was reduced and the left ventricular ejection fraction was improved in the BMSC group compared with the control group (P<0.05). Histopathological examination indicated that, in the BMSC treatment group, the percentage of survived myocardial tissue and the vessel density were increased, and the percentage of apoptosis was decreased compared with controls (P<0.05). Reverse transcription-polymerase chain reaction results indicated that the expression levels of multiple inflammatory factors were significantly upregulated in the BMSC group compared with levels in the control group (P<0.05). In conclusion, the present study demonstrated that BMSC injection significantly improved cardiac function and reduced infarct size in six months, indicating that this method may be valuable for future study in clinical trials. IntroductionAccording to 2011 statistics, acute myocardial infarction (AMI) is one of the most prevalent causes of death and morbidity (1,2). Adult cardiomyocytes lack the capacity for regeneration, so scar tissue replaces lost myocardium following myocardial infarction, and this leads to cardiac remodeling with reduced left ventricular (LV) function (3). Cell therapy is a potential method for the regeneration and repair of myocardium and the improvement of myocardial function following ischemic injury (4). A number of cell types, including foetal Flk1 + CD34 + CD31 -bone marrow stem cells (BMSCs) have demonstrated cardiac regenerative capacity (5), however, the mechanism that stem cell transplantation utilizes in order to improve cardiac function following ischemic heart disease is unclear and there is little information available regarding the medium-and long-term effects. On the other hand, there exist a variety of transplantation methods, including local intramyocardial injection, intravenous injection, and intracoronary injection to the infarct zone (6). Intramyocardial injection of BMSCs has been demonstrated to be safe, and to lead to reverse remodeling and improved contractile ability of scarred areas (3,7). The mechanisms by which BMSCs reduce infarct size and improve cardiac function in animal models are complicated, involving engraftment, differentiation into functional cardiomyocytes and paracrine signaling (8,9). In the present study, fetal Flk1 + CD34 + CD31 -BMSCs were transplanted via intramyocardial injection of the mini-swine, then the myocardial function, stem cell migration and extent of survival in the myocardium was evaluated. The current study was therefore designed to determine the long-term (6-month) e...

show abstract

Section: Discussionmentioning

confidence: 99%

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Zhao

Liu

Kong

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…The preparation of transmyocardial channel, bFGF, and heparin anticoagulated degradable stent has already been described in our earlier report [8]. In this study, each stent contained 15 mg of recombinant human bFGF (molecular mass 17.4 kDa, purity > 97%, R&D) and 25 mg of heparin (150 U/mg, Dingguo, Beijing, China).…”

Section: Preparation Of Transmyocardial Channel Bfgf and Heparin Anmentioning

confidence: 98%

“…Isolation, culture, immunophenotype analysis, and labeling of MSCs MSCs were isolated and cultured using the methods described earlier [8]. Immunophenotyping analysis was done by using the methods described earlier [11,12].…”

Section: Animalsmentioning

confidence: 99%

“…Basic fibroblast growth factor (bFGF), a family member of heparin-binding growth factors, has been shown to greatly contribute to neovascularization. We have developed [8] a new method -transmyocardial drilling revascularization (TMDR) -combined with a mechanical drilling procedure in the myocardium and implantation of a stent, newly developed in our institution, into the hole made by TMDR. The new stent is composed of poly-D,L-lactic/glycolic acid as the controlled release system of bFGF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mid-term effect of stem cells combined with transmyocardial degradable stent on swine model of acute myocardial infarction

Luan

Liu²,

Zhang

et al. 2010

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…Flow cytometric immunophenotyping was performed by using methods as our previously reported [18][19][20]: 5×10 5 cells were suspended with trypsin and were washed 2 times in phosphatebuffered saline (PBS). After centrifugation, the cells were incubated with primary against human CD44, CD29, CD34, and CD90 antibodies for 30 min at 4°C.…”

Section: Bmsc Preparation and Injectionmentioning

confidence: 99%

Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism

Luan

Zhang

Kong

et al. 2012

International Immunopharmacology

View full text Add to dashboard Cite

A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction

Cited by 19 publications

References 19 publications

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Bone marrow mesenchymal stem cells improve myocardial function in a swine model of acute myocardial infarction

Mid-term effect of stem cells combined with transmyocardial degradable stent on swine model of acute myocardial infarction

Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism

Contact Info

Product

Resources

About